Biological evaluation of an ornithine-modified 99mTc-labeled RGD peptide as an angiogenesis imaging agent

Nuclear Medicine and Biology

Volumn 40, Issue 2, 2013, Pages 262-272

  Tsiapa, Irene ^a   Loudos, George ^b   Varvarigou, Alexandra ^c   Fragogeorgi, Eirini ^b,c   Psimadas, Dimitrios ^b,c   Tsotakos, Theodoros ^b,c   Xanthopoulos, Stavros ^c   Mihailidis, Dimitris ^d   Bouziotis, Penelope ^c   Nikiforidis, George C ^a   Kagadis, George C ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF WEST ATTICA   (Greece)

^c INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^d Charleston Radiation Therapy Consultants ^*  (United States)

Author keywords

Chelator; Integrin 3; Ornithine; Radiolabeling; RGD; Technetium

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID TC 99M; CYSTEINYLGLYCYLGLYCINE; INTEGRIN RECEPTOR; ORNITHINE; PEPTIDE DERIVATIVE; RHENIUM; RHENIUM 185; RHENIUM 187; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EXCRETION; DRUG STABILITY; DRUG TARGETING; DRUG TUMOR LEVEL; EX VIVO STUDY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; RADIOCHEMISTRY; RECEPTOR BLOCKING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCINTIGRAPHY; URINARY EXCRETION;

ANIMALS; CELL LINE, TUMOR; DRUG STABILITY; FEMALE; HUMANS; ISOTOPE LABELING; MAGNETIC RESONANCE IMAGING; MICE; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; ORNITHINE; QUALITY CONTROL; RHENIUM; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84872968956     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.10.015     Document Type: Article

References (53)

1. Folkman J. Angiogenesis and apoptosis. Semin Cancer Biol 2003, 13:159-167.
2. Harris A.L. Angiogenesis as a new target for cancer control. EJC Suppl 2003, 1:1-12.
3. Makrilia N., Lappa T., Xyla V., Nikolaidis I., Syrigos K. The role of angiogenesis in solid tumours: an overview. Eur J Intern Med 2009, 20:663-671.
4. Liu Z., Wang F., Chen X. Integrin alpha(v)beta(3)-targeted cancer therapy. Drug Dev Res 2008, 69:329-339.
5. Jeswani T., Padhani A.R. Imaging tumour angiogenesis. Cancer Imaging 2005, 5:131-138.
6. Lim E.H., Danthi N., Bednarski M., Li K.C. A review: integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis. Nanomedicine 2005, 1:110-114.
7. Beer A.J., Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 2008, 27:631-644.
8. Dobrucki L.W., Sinusas A.J. Imaging angiogenesis. Curr Opin Biotechnol 2007, 18:90-96.
9. Garanger E., Boturyn D., Dumy P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem 2007, 7:552-558.
10. Haubner R. Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?. Eur J Nucl Med Mol Imaging 2006, 33(Suppl 1):54-63.
11. Haubner R., Wester H.J. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004, 10:1439-1455.
12. Schottelius M., Laufer B., Kessler H., Wester H.J. Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res 2009, 42:969-980.
13. Liu S. Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev 2008, 60:1347-1370.
14. Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 2009, 20:2199-2213.
15. Psimadas D., Fani M., Gourni E., Loudos G., Xanthopoulos S., Zikos C., et al. Synthesis and comparative assessment of a labeled RGD peptide bearing two different (9)(9)mTc-tricarbonyl chelators for potential use as targeted radiopharmaceutical. Bioorg Med Chem 2012, 20:2549-2557.
16. Bach-Gansmo T., Bogsrud T.V., Skretting A. Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692. Clin Physiol Funct Imaging 2008, 28:235-239.
17. Decristoforo C., Faintuch-Linkowski B., Rey A., von Guggenberg E., Rupprich M., Hernandez-Gonzales I., et al. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression. Nucl Med Biol 2006, 33:945-952.
18. Decristoforo C., Hernandez Gonzalez I., Carlsen J., Rupprich M., Huisman M., Virgolini I., et al. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2008, 35:1507-1515.
19. Liu Z., Jia B., Shi J., Jin X., Zhao H., Li F., et al. Tumor uptake of the RGD Dimeric Probe (99m)Tc-G(3)-2P(4)-RGD2 is Correlated with Integrin alpha(v)beta(3) Expressed on both tumor cells and neovasculature. Bioconjug Chem 2010.
20. Chen J., Giblin M.F., Wang N., Jurisson S.S., Quinn T.P. In vivo evaluation of 99mTc/188Re-labeled linear alpha-melanocyte stimulating hormone analogs for specific melanoma targeting. Nucl Med Biol 1999, 26:687-693.
21. Mahmood A., Jones A.G. Technetium radiopharmaceuticals. Handbook of Radiopharmaceuticals 2003, John Wiler & Sons Ltd., Chichester, West Sussex, England. M.J. Welch, C.S. Redvanly (Eds.).
22. Fragogeorgi E.A., Zikos C., Gourni E., Bouziotis P., Paravatou-Petsotas M., Loudos G., et al. Spacer site modifications for the improvement of the in vitro and in vivo binding properties of (99m)Tc-N(3)S-X-bombesin[2-14] derivatives. Bioconjug Chem 2009, 20:856-867.
23. Gourni E., Bouziotis P., Benaki D., Loudos G., Xanthopoulos S., Paravatou-Petsotas M., et al. Structural assessment and biological evaluation of two N3S bombesin derivatives. J Med Chem 2009, 52:4234-4246.
24. Grummon G., Rajagopalan R., Palenik G.J., Koziol A.E., Nosco D.L. Synthesis, characterization and crystal structures of technetium(V)-Oxo complexes useful in nuclear medicine. 1. Complexes of mercaptoacetylglycylglycylglycine (MAG3) and its methyl ester derivative (MAG3OMe). Inorg Chem 1995, 34:1764-1772.
25. Liolios C.C., Fragogeorgi E.A., Zikos C., Loudos G., Xanthopoulos S., Bouziotis P., et al. Structural modifications of (9)(9)mTc-labelled bombesin-like peptides for optimizing pharmacokinetics in prostate tumor targeting. Int J Pharm 2012, 430:1-17.
26. Wong E., Fauconnier T., Bennett S., Valliant J., Nguyen T., Lau F., et al. Rhenium(V) and technetium(V) Oxo complexes of an N(2)N'S peptidic chelator: evidence of interconversion between the syn and anti conformations. Inorg Chem 1997, 36:5799-5808.
27. Smith C.J., Gali H., Sieckman G.L., Higginbotham C., Volkert W.A., Hoffman T.J. Radiochemical investigations of (99m)Tc-N(3)S-X-BBN[7-14]NH(2): an in vitro/in vivo structure-activity relationship study where X = 0-, 3-, 5-, 8-, and 11-carbon tethering moieties. Bioconjug Chem 2003, 14:93-102.
28. Ferro-Flores G., Ramirez F.de M., Melendez-Alafort L., Santos-Cuevas C.L. Peptides for in vivo target-specific cancer imaging. Mini Rev Med Chem 2010, 10:87-97.
29. Kiessling F., Huppert J., Zhang C., Jayapaul J., Zwick S., Woenne E.C., et al. RGD-labeled USPIO inhibits adhesion and endocytotic activity of alpha v beta3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology 2009, 253:462-469.
30. Loudos G., Kagadis G.C., Psimadas D. Current status and future perspectives of in vivo small animal imaging using radiolabeled nanoparticles. Eur J Radiol 2011, 78:287-295.
31. Ting G., Chang C.H., Wang H.E., Lee T.W. Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. J Biomed Biotechnol 2010.
32. Loudos G., Majewski S., Wojcik R., Weisenberger A., Sakellios N., Nikita K., et al. Performance evaluation of a dedicated camera suitable for dynamic radiopharmaceuticals evaluation in small animals. IEEE Trans Nucl Sci 2007, 54:454-460.
33. Noll B., Kniess T., Fruebe M., Spies H., Johannsen B. Rhenium(V) Gluconate, a suitable precurson for the preparation of Rhenium(V) complexes. Isotopes Environ Health Stud 1996, 32:21-29.
34. Lee D.E., Hong Y.D., Choi K.H., Lee S.Y., Park P.H., Choi S.J. Preparation and evaluation of 99mTc-labeled cyclic arginine-glycine-aspartate (RGD) peptide for integrin targeting. Appl Radiat Isot 2010, 68:1896-1902.
35. Beer A.J., Haubner R., Goebel M., Luderschmidt S., Spilker M.E., Wester H.J., et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005, 46:1333-1341.
36. Chen X., Park R., Shahinian A.H., Bading J.R., Conti P.S. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl Med Biol 2004, 31:11-19.
37. Chen X., Park R., Tohme M., Shahinian A.H., Bading J.R., Conti P.S. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 2004, 15:41-49.
38. Haubner R., Weber W.A., Beer A.J., Vabuliene E., Reim D., Sarbia M., et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005, 2:e70.
39. Liu S. Radiolabeled multimeric cyclic RGD peptides as integrin alphavbeta3 targeted radiotracers for tumor imaging. Mol Pharm 2006, 3:472-487.
40. Liu S., Cheung E., Ziegler M.C., Rajopadhye M., Edwards D.S. (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjug Chem 2001, 12:559-568.
41. Temming K., Schiffelers R.M., Molema G., Kok R.J. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 2005, 8:381-402.
42. Liu S., Edwards D.S. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem 2001, 12:7-34.
43. Chen X. Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem 2006, 6:227-234.
44. Chen X., Park R., Shahinian A.H., Tohme M., Khankaldyyan V., Bozorgzadeh M.H., et al. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol 2004, 31:179-189.
45. Lee S., Xie J., Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev 2010, 110:3087-3111.
46. Okarvi S.M. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004, 24:357-397.
47. Van de Wiele C., Dumont F., van Belle S., Slegers G., Peers S.H., Dierckx R.A. Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging?. Nucl Med Commun 2001, 22:5-15.
48. Alves S., Correia J.D., Santos I., Veerendra B., Sieckman G.L., Hoffman T.J., et al. Pyrazolyl conjugates of bombesin: a new tridentate ligand framework for the stabilization of fac-[M(CO)3]+ moiety. Nucl Med Biol 2006, 33:625-634.
49. Akizawa H., Uehara T., Arano Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv Drug Deliv Rev 2008, 60:1319-1328.
50. Psimadas D., Baldi G., Ravagli C., Bouziotis P., Xanthopoulos S., Franchini M.C., et al. Preliminary evaluation of a 99mTc labeled hybrid nanoparticle bearing a cobalt ferrite core: in vivo biodistribution. J Biomed Nanotechnol 2012, 8:575-585.
51. Psimadas D., Georgoulias P., Valotassiou V., Loudos G. Molecular nanomedicine towards cancer: (1)(1)(1)In-labeled nanoparticles. J Pharm Sci 2012, 101:2271-2280.
52. de Jong M., Rolleman E.J., Bernard B.F., Visser T.J., Bakker W.H., Breeman W.A., et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo. J Nucl Med 1996, 37:1388-1392.
53. Gotthardt M., van Eerd-Vismale J., Oyen W.J., de Jong M., Zhang H., Rolleman E., et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med 2007, 48:596-601.